Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care, Biosensors & Mobile Diagnostics Europe 2021

Point-of-Care, Biosensors & Mobile Diagnostics Europe 2021 Agenda

Co-Located Conference Agendas

3D-Culture, Organoids & Organ-on-a-Chip Europe 2021 | Lab-on-a-Chip and Microfluidics Europe 2021 | Point-of-Care, Biosensors & Mobile Diagnostics Europe 2021 | 

Print Agenda

Monday, 28 June 2021

Full Details of Day 1 Agenda -- Please Check the Lab-on-a-Chip Europe 2021 Agenda

Tuesday, 29 June 2021

Full Details of Day 2 Agenda -- Please Check the Organoids and Organ-on-a-Chip Europe 2021 Agenda

Wednesday, 30 June 2021


Morning Coffee, Pastries and Networking


Peter ErtlKeynote Presentation

Self-Powered Microfluidic Electrical Sensor Array to Rapidly Detect Viral Contaminations in Liquid Solutions
Peter Ertl, Professor of Lab-on-a-Chip Systems, Vienna University of Technology, Austria

The incidence of viral distribution and infection has soared over the past decades due to population growth, deforestation and increased travel, resulting in a global pandemic caused by SARS-CoV-2 viral outbreak. As a consequence, rapid detection and identification of viral infections is a pressing human health issue. Faster, more accurate diagnosis will benefit health care systems in particular, by significantly reducing time-to-result and providing better more reliable epidemiological data that can be used for infectious disease control. In course of the presentation current Covid-19 test kits are reviewed and evaluated for point-of-care and on-site applications. Additionally, our efforts to develop a self-powered sensing solution combining liquid handling unit, microbatteries, optical read out and microsensor arrays within a stand-alone lab-on-a-chip system will be presented.


Menno PrinsKeynote Presentation

Continuous Biomarker Monitoring with Single-Molecule Resolution
Menno Prins, Professor, Eindhoven University of Technology & Helia BioMonitoring, Netherlands

Single-molecule techniques have become impactful in bioanalytical sciences because of their high detection sensitivity and digital quantitation. However, in the upcoming field of sensors for continuous biomolecular monitoring, the advantages of single-molecule methodologies are yet to be discovered. Here, I will describe a biosensing technology for the continuous monitoring of biomolecular targets, based on measuring the Brownian motion of tethered particles. The sensor consists of particles tethered to a surface, where the particles as well as the surface are provided with specific binder molecules. Motion time traces are recorded of hundreds of particles, each revealing digital binding and unbinding events. The events are statistically analyzed and related to the biomarker concentration in solution. Large molecules (proteins, nucleic acids) and small molecules (metabolites, hormones, oligonucleotides) have been measured, across a wide range of concentrations (picomolar to millimolar). In this talk I will describe the BPM sensing principle (Biosensing based on Particle Motion), show experimental results, and discuss applications in industry and healthcare, for early warning and closed-loop control based on real-time biochemical data.


Towards Large Scale Integrated, Multivariate “Lab-on-a-Disc” Sensors by a Virtual “Digital Twin” Approach
Jens Ducrée, Doctor, Dublin City University, Ireland

Future decentralized bioanalytical testing, e.g., for applications in point-of-care and global diagnostics as well as ubiquitous monitoring of industries, infrastructures and the environment, will require full sample-to-answer automation and parallelization of bioassays on widely autonomous or user-friendly, robust and cost-efficient systems. Centrifugal microfluidic technologies have already demonstrated comprehensive, high-performance process integration of bioassay protocols for a wide range of scientific endeavours and commercial applications. Based on a digital twin approach, this presentation outlines a virtual “in silico” approach to optimize performance, integration density, reliability, configurability and manufacturability of these “Lab-on-a-Disc” (LoaD) devices, thus decisively minimizing cost, risk and time-to-market. These advancements provide an entry gate for developing mature commercial supply chains, foundry services, standardization, validation, and even enable rapidly emerging, participatory research models based on disruptive 21st technologies at the crossroads of Internet of Things (IoT), Artificial Intelligence (AI) and the distributed ledger technology Blockchain.


Morning Coffee Break and Networking


Actin Filament Multiplication, Path Control and Longevity of Actin-Myosin based Nanodevices for Biosensing and Biocomputation
Alf Månsson, Professor, Linnaeus University and Lund University Sweden, Sweden

Biomolecular myosin motors interact with actin filaments in utilizing the cellular fuel ATP to produce motion and forces, e.g. in muscle contraction and cytoplasmic streaming in plant cells. Both isolated motors and actin filaments have been chemically and genetically engineered for use in nanotechnological applications. In the devices, myosin motor fragments are immobilized on suitably derivatized nanoscale tracks for directed movement of actin filaments in network based biological computation or to separate analyte molecules and accumulate them on a detector area. For greater versatility of such nanodevices it is important to extend the shelf-life during storage as well as the longevity during device operation. For several applications it is also desirable to exponentially increase the number of filaments during operation, e.g. by repeated cycles of actin severing using gelsolin followed by elongation, and to precisely and remotely control the exact filament path through the network. Improved longevity requires rationally determined adjustments of the fluid environment and device fabrication. Here, I describe recent progress in these regards and their importance for improved molecular motors based nanodevices.


Combined Calorimetric Gas- and Spore-based Biosensor for Aseptic Food Processing
Michael Schöning, Professor and Director, Institute of Nano- and Biotechnologies, Aachen University of Applied Sciences, Germany

Gaseous H2O2 represents one of the most used sterilization agents in aseptic food processing. To validate this sterilization method under investigation, robust spores that are resistant against this sterilant are first exposed. Afterwards, the logarithmic kill rate (i.e., how many survived from them) is determined by time-consuming (48-72 h) and tedious microbiological count-plating methods (e.g., count reduction test, end point test). A novel sensing method is introduced, consisting of a spore-based biosensor, which is combined with a calorimetric H2O2 sensor onto a single chip to evaluate both the viability of the spores and to determine the gaseous H2O2 concentration. The calorimetric gas sensor responds to different concentrations of gaseous H2O2 via change of its initial resistance, whereas the spore-based biosensor monitors the spore degradation, depending on the H2O2 concentration detecting the impedance variation. Three different strains of spores were investigated with regard to the H2O2 durability, namely B. atrophaeus DSM 675, B. subtilis DSM 402 and G. stearothermophilus DSM 5934. The two sensor types were combined as sensor array enabling a considerably more specific multi-parameter experience in aseptic filling machines in comparison to isolated microbiological state-of-the-art- or hydrogen peroxide methods.


Lunch and Networking


Martyn BoutelleKeynote Presentation

Closing Keynote Presentation: Novel Microfluidic Approaches to Real-Time Tissue Monitoring
Martyn Boutelle, Professor of Biomedical Sensors Engineering, Imperial College London, United Kingdom

The idea of making decisions, using for example AI, based on an information stream is influencing all aspects of life. In Healthcare this is emerging as the personalization of healthcare – where data is used to track the progression of illness and the effects of treatment in a patient at the individual level, rather than using the population average. To do this using biomolecular information requires combinations of microfluidic devices, sensors and electronics designed to embed analytical best practice. I will present recent work on new types of microfluidic devices for monitoring human tissue and the brain.


Small-Molecule Quantification for Point-of-Care Testing Using Paper-based Analytical Devices
Jean-Manuel Segura, Professor, University of Applied Sciences and Arts Western Switzerland Valais, Switzerland

Paper offers many advantages as a material to produce point-of-care (POC) diagnostic tests: Paper-based analytical devices (PAD) are cheap, amenable for mass manufacturing, easy to dispose after use and do not require external actuation. Many important biomarkers tested using PADs are small molecules. While some analytes such as glucose can be analyzed using enzymatic assays, most are quantified using competitive immunoassays, which require well-defined concentrations of the reagents (antibodies and tracers). This is not easy to achieve in a POC format, might result in assay variability and renders assay design more complex.  During this talk, I will present two examples how competitive immunoassays can be implemented in paper-based analytical devices for POC applications. In a first example, I will describe the development of a lateral flow assay for salivary cortisol, a biomarker of chronic stress. The low concentration and the stringent requirements on assay precision make the development of such a test challenging. A detailed understanding of the underlying immunoassay mechanism enabled a considerable improvement of the performance. In a second example, I will discuss the development of a vertical flow assay for the antibiotics tobramycin, which requires therapeutic drug monitoring to ensure efficacy while avoiding oto- and nephrotoxicity. A homogeneous competitive immunoassay based on fluorescence polarization was implemented inside paper microzones that enabled both plasma extraction and detection.


John T McDevittKeynote Presentation

Development and Deployment of a 'Smart Diagnostic Ecosystem' for Covid-19 and Beyond: Near Real-Time Customization of Programmable Medical Microdevices
John T McDevitt, Chair, Department of Biomaterials, New York University College of Dentistry Bioengineering Institute, United States of America

SARS-CoV-2, the virus that causes coronavirus disease (COVID-19), has reached pandemic levels and resulted in significant morbidity and mortality that has affected every inhabited continent. Delays in diagnostic testing and the inability to track infections on a local, international and global basis has hampered the management of the COVID19 pandemic. This pathogenic coronavirus has had a disproportionate impact on the underserved and impoverished. While COVID-19 has yielded devastating consequences, the pandemic has also opened the door for acceleration of core diagnostic capabilities that have the potential to lead to lasting impact for our society. With this vantage point in mid, in the recent past we have launched a series of efforts that target the development and deployment of a ‘smart diagnostics ecosystem’. Here we integrate programmable chip-based diagnostic systems capable of multiplexed measurements alongside clinical decision support tools that utilize strategically chosen nonclinical data elements that elicit signatures that can be used to capture diseases before they spiral out of control, including COVID-19. Using newly established diagnostic models that leverage large COVID-19 databases we have developed, validated and scaled a clinical decision support system and mobile app to assist in COVID-19 severity assessment, management, and care. Model training data from 701 patients with COVID-19 were collected across practices within the Family Health Centers network at New York University Langone Health. A two-tiered model was developed. Tier 1 uses easily available, nonlaboratory data to help determine whether biomarker-based testing and/or hospitalization is necessary. Tier 2 predicts probability of mortality using biomarker measurements (CRP, PCT, D-dimer) and age. Both Tier 1 and Tier 2 models were validated using two external datasets from hospitals in Wuhan, China comprising 160 and 375 patients, respectively. These capabilities have been extended recently to screening of dental patients as well as to the developments of on integrated immunity scoring system. The ecosystem now includes cloud connected databases and AI linked clinical decision support tools that were developed initially for COVID-19, but are now helping to accelerate the arrival of new oncology tools.


Afternoon Coffee Break and Networking


An Advanced Statistical Description of Digital Quantification Methods and its Implications for the Design of Point-of-Care Devices
Manuel Loskyll, Researcher, Robert Bosch GmbH, Germany

In partition-based digital quantification, statistical processes like partitioning and sub-sampling influence the uncertainty of the experiment’s result. The presented analysis of these processes helps to design point-of-care devices providing an optimized quantification accuracy, while using a limited area for evaluation.


Accelerating CAR T-cell Immunotherapy Research with Assistance of Nano-biosensors
Trang Anh Nguyen Le, Researcher, Helmholzt Center Dresden Rossendorf, Germany

Silicon nanowire field-effect transistors with outstanding sensitivity enable screening for best molecule during construction of UniCAR T cell therapy.


Interdigitated Gold Nanowires for Impedimetric Detection of SARS-CoV-2 Antibodies
Diana Isabel Sandoval Bojorquez, Researcher, Helmholtz Zentrum Dresden Rossendorf, Germany

We developed a biosensor for the detection of antibodies that are present during and after infection with SARS-CoV-2. Detection was performed by monitoring the changes in the surface of interdigitated gold nanowires with the electrical impedance spectroscopy technique.


Close of Conference

Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2021Point-of-Care, Biosensors and Mobile Diagnostics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The